Atrium Launches with $270M to Pioneer RNA Heart Disease Therapies

SAN DIEGO, CA – February 27, 2026 – A new player in the high-stakes world of biotechnology launched today, armed with a formidable war chest and a mission to conquer some of the most intractable genetic heart diseases. Atrium Therapeutics, Inc. began trading on the Nasdaq under the ticker symbol "RNA," debuting as an independent company with approximately $270 million in cash and a sharp focus on delivering novel RNA-based medicines directly to the heart.

The company emerges from the shadow of a massive pharmaceutical acquisition, having been spun off from Avidity Biosciences as part of its $12 billion takeover by Novartis. This strategic move allows Atrium to dedicate its resources and specialized technology to a promising but early-stage pipeline targeting rare cardiomyopathies, conditions that currently have no cure.

Leading the new venture is President and CEO Kathleen Gallagher, a veteran of Avidity Biosciences. "The launch of Atrium Therapeutics marks an important milestone for people living with genetic cardiomyopathies," Gallagher stated in the company's inaugural press release. "Patients and families facing these genetically driven rare cardiomyopathies have few if any options that address the underlying cause. Building on Avidity's pioneering work in targeted RNA delivery, Atrium is positioned to advance precision medicines designed to directly target the biologic drivers of cardiac disease."

A Strategic Spinoff from a Biotech Blockbuster

Atrium's genesis is directly tied to Novartis's strategic acquisition of Avidity Biosciences, a deal finalized today. Novartis was primarily interested in Avidity's late-stage pipeline and its proven platform for targeting rare neuromuscular diseases. The acquisition agreement, first announced in October 2025, stipulated that Avidity's nascent but promising precision cardiology programs would be carved out into a separate, independent entity.

This spinoff structure provided a clear path for both companies. Novartis integrated Avidity's muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and its advanced clinical programs, while Atrium was born with a clean balance sheet, significant funding, and the rights to apply the same core technology to cardiac tissue. Shareholders of Avidity as of February 12, 2026, received one share of Atrium for every ten Avidity shares they held, making them the initial owners of the new enterprise.

Now fully independent, Atrium has no continuing ownership interest from Novartis or the newly acquired Avidity. The company is helmed by a leadership team deeply familiar with the technology and its potential. CEO Kathleen Gallagher previously served as Chief Program Officer at Avidity, where she was instrumental in guiding its small interfering RNA (siRNA) assets toward clinical trials. She is joined by Sarah Boyce, the former CEO of Avidity, who now serves as Chair of Atrium's board of directors.

"As Atrium Therapeutics embarks on a new chapter today, I am incredibly proud of the team's commitment to advancing groundbreaking science for people with genetically driven cardiomyopathies," said Boyce. "Precision cardiology is an area of immense opportunity, and I am confident the Atrium Therapeutics team's experiences in rare disease, drug development and RNA therapeutics and patient-focused approach will urgently move its pipeline forward."

The New Frontier: Targeting the Heart with RNA

At the core of Atrium's strategy is a sophisticated drug delivery platform designed at Avidity. The technology utilizes Antibody Oligonucleotide Conjugates (AOCs) to solve one of the biggest challenges in medicine: getting complex drugs to the right cells while avoiding others. The heart has historically been a notoriously difficult organ to target with RNA therapies.

Atrium's platform works by attaching a small interfering RNA (siRNA) molecule—a precision tool for silencing disease-causing genes—to a monoclonal antibody. The antibody acts as a biological GPS, homing in on specific receptors on the surface of heart muscle cells. Once bound, the cell internalizes the entire conjugate, releasing the siRNA payload to do its work inside. This non-viral approach avoids many of the safety and manufacturing challenges associated with gene therapies that use viruses as delivery vehicles.

By leveraging this technology, Atrium aims to create a new class of precision medicines that can directly address the genetic root cause of specific cardiac diseases, rather than just managing symptoms. The company's pipeline already includes two lead candidates poised to test this revolutionary approach.

Hope for Untreatable Cardiomyopathies

Atrium's initial focus is on two rare, life-threatening, and progressive genetic disorders with significant unmet needs. For the thousands of patients affected, current medical care is limited to managing symptoms like arrhythmias and heart failure, with heart transplantation often being the only long-term solution.

Its most advanced candidate, ATR 1072, targets PRKAG2 syndrome. This condition is caused by a genetic mutation that leads to excessive glycogen accumulation in heart muscle cells, causing the heart to thicken and develop severe electrical problems. Atrium's therapy is designed to silence the mutated gene, reduce the toxic buildup, and potentially restore normal cardiac function. The company is already conducting Investigational New Drug (IND)-enabling studies and expects to file for FDA approval to begin human trials in the second half of 2026.

Its second candidate, ATR 1086, is being developed for PLN cardiomyopathy. This disease results from a mutation in the phospholamban gene, disrupting calcium regulation in heart cells and leading to arrhythmias, heart failure, and a high risk of sudden cardiac death. ATR 1086 aims to reduce the production of the faulty PLN protein. Atrium plans to initiate IND-enabling studies for this program in 2026, with a target IND submission in 2027.

Success with either of these programs would not only provide a desperately needed treatment but also validate Atrium's entire platform for targeting the heart, opening the door to treatments for a wider range of genetic cardiac conditions.

Wall Street's Cautious Welcome

Despite the promising science and substantial initial funding of $270 million, Atrium's market debut was met with a cautious reception. In pre-market trading, shares (Nasdaq: RNA) were down approximately 4.5%. This type of initial selling pressure is not uncommon for spinoffs, as original shareholders who received stock may not have the risk appetite for a preclinical-stage biotech and choose to sell their newly acquired shares.

For investors, the central question is whether Atrium's potential outweighs the inherent risks. The $270 million in capital provides a healthy runway to advance its lead programs into the clinic, a critical phase where many biotech companies falter. The company's future now hinges on its ability to translate its groundbreaking science into clinical data.

The upcoming IND filings for ATR 1072 and ATR 1086 will be the first major tests for the fledgling company. The company's ability to navigate these early regulatory hurdles and ultimately deliver on its scientific promise will be closely watched by patients, physicians, and investors alike.